Mendelian Randomization Study Linking Immune Cells and Metabolites to Liver Cancer

A 2026 study by Zhipeng Ye presents results from a two-sample Mendelian randomization analysis investigating causal links between immune cell profiles, blood metabolites, and intrahepatic cholangiocarcinoma. The dataset likely contains statistical results, including odds ratios and confidence intervals for specific immune traits identified as risk factors. Experimental validation targeting the DLAT-leucine metabolic axis in HuCC-T1 and RBE cells is also described.

Use Cases

• Validate causal inference findings based on Mendelian randomization results for specific immune cell phenotypes.
• Investigate the role of N-acetylleucine and fructosyllysine as metabolic mediators between immune traits and cancer risk.
• Design follow-up in vitro experiments based on the identified DLAT-leucine metabolic axis.
• Perform meta-analyses on genetic risk factors for intrahepatic cholangiocarcinoma using the reported odds ratios.

Strengths

• Includes results from sensitivity analyses confirming no horizontal pleiotropy or heterogeneity.
• Reports specific odds ratios and p-values for three immune traits linked to cancer risk.
• Combines genetic analysis with in vitro experimental validation in two cell lines (HuCC-T1 and RBE).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (32.2 KB), indicating limited scope, likely containing summary results rather than raw genetic data.

Provenance

Source

Zhipeng Ye via figshare

Collection Method

Two-sample Mendelian randomization analysis with mediation analysis and in vitro cell experiments.

Freshness

Last updated 2026-05-22 06:10:30; freshness should be verified.